Nima Farzan, CEO of Kinnate Biopharma Inc., a precision oncology company, discusses the company’s investigational targeted cancer therapies which are designed to target validated oncogenic drivers for patients who are not served or severely underserved today, such as patients with solid tumors harboring BRAF and FGFR-driven alterations.
Nima Farzan brings over two decades of executive leadership experience in the biopharma industry to Kinnate. Prior to joining Kinnate, Nima spent seven years at PaxVax, where he was most recently President and CEO. While there, he successfully led a team of 250 people through a number of commercial product launches and negotiated the sale of PaxVax to Emergent BioSolutions in 2018. Prior to PaxVax, he was at Novartis AG in a series of roles of increasing responsibility, most recently as Vice President of US Marketing at Novartis’ Vaccines and Diagnostics division. Prior to Novartis, Nima worked at DoubleTwist, a pioneering genomics company, and was a consultant with Boston Consulting Group. He was a member of the founding Board of the Coalition for Epidemic Preparedness Innovations (CEPI). He is on the Executive Committee of the Northern California Chapter of Young President’s Organization (YPO) and a Trustee at the Hamlin School. He is also a Director of Keros Therapeutics (NASDAQ: KROS). He holds a BA in Human Biology from Stanford University and an MBA from Harvard Business School.